John R. Chiminski
Net Worth
Last updated:
What is John R. Chiminski net worth?
The estimated net worth of Mr. John R. Chiminski is at least $161,800,750 as of 25 Aug 2022. He has earned $130,100,750 from insider trading and has received compensation worth at least $31,700,000 in Catalent, Inc..
What is the salary of John R. Chiminski?
Mr. John R. Chiminski salary is $3,170,000 per year as Chairman & Chief Executive Officer in Catalent, Inc..
How old is John R. Chiminski?
Mr. John R. Chiminski is 61 years old, born in 1964.
What stocks does John R. Chiminski currently own?
As insider, Mr. John R. Chiminski owns shares in one company:
Company | Title | Shares | Price per share | Total value |
---|---|---|---|---|
Catalent, Inc. (CTLT) | Chairman & Chief Executive Officer | 229,888 | $0 | $0 |
What does Catalent, Inc. do?
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials. It also offers FastChain demand-led clinical supply services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was incorporated in 2007 and is headquartered in Somerset, New Jersey.
John R. Chiminski insider trading
Catalent, Inc.
Mr. John R. Chiminski has made 21 insider trades between 2015-2022, according to the Form 4 filled with the SEC. Most recently he sold 38,934 units of CTLT stock worth $4,011,759 on 25 Aug 2022.
The largest trade he's ever made was exercising 286,358 units of CTLT stock on 1 Oct 2018. As of 25 Aug 2022 he still owns at least 229,888 units of CTLT stock.
Catalent key executives
Catalent, Inc. executives and other stock owners filed with the SEC:
- Mr. Alessandro Maselli (53) Pres & Chief Operating Officer
- Mr. John R. Chiminski (61) Chairman & Chief Executive Officer
- Mr. Steven L. Fasman (62) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Thomas P. Castellano (45) Senior Vice President & Chief Financial Officer
- Ms. Karen A. Flynn (62) Chief Commercial Officer